Number of items: 3.
2011
Weller, M.,
Gorlia, T.,
Cairncross, J. G.,
van den Bent, M. J. 
,
Mason, W.,
Belanger, K.,
Brandes, A. A. 
,
Bogdahn, Ulrich,
Macdonald, D. R.,
Forsyth, P.,
Rossetti, A. O. 
,
Lacombe, D.,
Mirimanoff, R.-O.,
Vecht, C. J. and
Stupp, R.
(2011)
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Neurology 77 (12), pp. 1156-1164.
Fulltext not available.
2008
Dresemann, G.,
Hosius, C.,
Lilienthal, J.,
Schleyer, E.,
Bogdan, U.,
Weller, M. and
Paulus, W.
(2008)
Treatment failure due to intracerebral stem cell-like behavior of glioblastoma (GBM) cells: A reason for targeted maintenance therapy with imatinib (I) and hydroxyurea (H)? An analysis of study DE21 and DE40 (Ambrosia).
Journal of Clinical Oncology 26 (15_sup), p. 2048.
Fulltext not available.
2005
Herrlinger, Ulrich,
Steinbrecher, A.,
Rieger, J.,
Hau, Peter,
Kortmann, R.-D.,
Meyermann, R.,
Schabet, M.,
Bamberg, M.,
Dichgans, J.,
Bogdahn, U. and
Weller, M.
(2005)
Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse.
Journal of neurology 252 (3), pp. 291-299.
Fulltext not available.
This list was generated on Fri Apr 10 22:31:17 2026 CEST.